Latest:
Burnout in Doctors and Mitigation Strategies
What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Herbert A. Eradat, MD
Latest:
Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL
Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Herve Tilly, MD, PhD
Latest:
Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL
Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.
Hetty Carraway
Latest:
Dr. Carraway on Aza-Nucleoside Combinations in MDS
Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).
Hiroji Iwata, MD, PhD
Latest:
Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC
Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.
Hisham Mehanna, PhD, BMedSc, MBChB, FRCS
Latest:
Dr. Mehanna on the Design of the De-ESCALaTE Trial in HPV+ Head and Neck Cancer
Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery, director, Institute of Head and Neck Studies and Education at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses the design of the De-ESCALaTE trial in patients with HPV-positive head and neck cancer.
Holger L. Gieschen, MD
Latest:
Dr. Gieschen on Toxicities Associated With Radiation Therapy in Prostate Cancer
Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.
Holly G. Prigerson, PhD
Latest:
Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer
Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.